Aberrant lineage specification of skeletal stem cells (SSCs) contributes to reduced bone mass and increased marrow adipose tissue (MAT) in osteoporosis and skeletal aging. Although master regulators of osteoblastic and adipogenic lineages have been identified, little is known about factors that are associated with MAT accumulation and osteoporotic bone loss. Here, we identify peroxisome-proliferator-activated receptor γ coactivator 1-α (PGC-1α) as a critical switch of cell fate decisions whose expression decreases with aging in human and mouse SSCs. Loss of PGC-1α promoted adipogenic differentiation of murine SSCs at the expense of osteoblastic differentiation. Deletion of PGC-1α in SSCs impaired bone formation and indirectly promoted bone resorption while enhancing MAT accumulation. Conversely, induction of PGC-1α attenuated osteoporotic bone loss and MAT accumulation. Mechanistically, PGC-1α maintains bone and fat balance by inducing TAZ. Our results suggest that PGC-1α is a potentially important therapeutic target in the treatment of osteoporosis and skeletal aging.
Pubmed ID: 30017591 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This unknown targets NFkB p65 Antibody
View all literature mentionsThis monoclonal targets anti Perilipin-1
View all literature mentionsThis polyclonal targets BGLAP
View all literature mentionsThis polyclonal targets Cleaved Caspase-3 (Asp175)
View all literature mentionsThis polyclonal targets NRF1
View all literature mentionsThis polyclonal targets Estrogen-related Receptor alpha
View all literature mentionsThis monoclonal targets Ly-6A/E
View all literature mentionsThis monoclonal targets CD45
View all literature mentionsThis monoclonal targets CD29
View all literature mentionsThis monoclonal targets CD11b
View all literature mentionsThis polyclonal targets
View all literature mentionsThis polyclonal targets YAP (H-125)
View all literature mentionsThis monoclonal targets α-Tubulin
View all literature mentionsThis polyclonal targets Human TAZ
View all literature mentionsThis polyclonal targets Human FABP4
View all literature mentionsThis polyclonal targets PGC1 alpha
View all literature mentionsMus musculus with name B6.129X1-Ppargc1atm1Dpk/J from IMSR.
View all literature mentionsMus musculus with name B6;129S4-Gt(ROSA)26Sortm1Sor/J from IMSR.
View all literature mentionsMus musculus with name B6.129(Cg)-Leprtm2(cre)Rck/J from IMSR.
View all literature mentionsMus musculus with name B6.Cg-Tg(Prrx1-cre)1Cjt/J from IMSR.
View all literature mentionsMus musculus with name B6N.129(FVB)-Ppargc1atm2.1Brsp/J from IMSR.
View all literature mentionsMus musculus with name FVB-Tg(tetO-Ppargc1a)1Dpk/J from IMSR.
View all literature mentionsMus musculus with name B6.Cg-Tg(Prrx1-cre)1Cjt/J from IMSR.
View all literature mentionsMus musculus with name B6.129(Cg)-Leprtm2(cre)Rck/J from IMSR.
View all literature mentionsMus musculus with name B6;129S4-Gt(ROSA)26Sortm1Sor/J from IMSR.
View all literature mentionsMus musculus with name FVB-Tg(tetO-Ppargc1a)1Dpk/J from IMSR.
View all literature mentionsMus musculus with name B6N.129(FVB)-Ppargc1atm2.1Brsp/J from IMSR.
View all literature mentionsMus musculus with name B6.129X1-Ppargc1atm1Dpk/J from IMSR.
View all literature mentions